Funding for this research was provided by:
National Institutes of Health (CA215471, CA76584, CA168611, CA206105)
The Pancreatic Cancer Action network Translational Research Grant
Received: 6 May 2019
Accepted: 14 July 2020
First Online: 24 August 2020
: M.P. has financial interests in CullGen Inc. and Kymera Therapeutics. M.P. is on the SAB of CullGen Inc. and Kymera Therapeutics. M.P. is a consultant for BeyondSpring Pharmaceuticals, CullGen Inc., Kymera Therapeutics, Exo Therapeutics and SEED Therapeutics. The other authors declare no competing interests.